Top cancer drugs based on revenue worldwide 2018

In 2018, Celgene’s Revlimid generated over eight billion U.S. dollars, making it the number one ranking cancer drug worldwide in terms of revenue that year. Other oncology products among the top ten included Opdivo, Herceptin, and Imbruvica.

Pharmaceutical outlook

In 2024, the top pharmaceutical product (in terms of revenue) is projected to be Keytruda by Merck & Co. Worldwide revenue for this drug is expected to reach 17 billion U.S. dollars that year. Pharmaceutical sales numbers are forecast to be the highest in North America in 2022. It is predicted that sales numbers will reach over 600 billion U.S. dollars, which is more than double the sales numbers expected from the runner-up, Europe.

Cancer cases by gender

Specific types of cancer are more common among certain genders. Worldwide, breast cancer accounted for approximately a quarter of all new cancer cases among females of all ages in 2018. Colorectal cancer was the second most common type for women. For men, lung and prostate cancer were the most common that year. Almost 15 percent of new male cases, involved lung cancer, while about 13 percent were prostate cancer cases.

Top 10 cancer drugs worldwide by revenue in 2018

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% Discount until June 30th
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

April 2019

Region

Worldwide

Survey time period

2018

Open this statistic in...
Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Oncology"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.